Distress
Karyopharm files Chapter 11 with Ayrmid merger plan that cancels its common stock
Lenders and noteholders would own 55% of the combined company and receive myelofibrosis sales rights. Shareholders get nothing, and Karyopharm expects its stock to be delisted.

Karyopharm Therapeutics (Nasdaq: KPTI) filed for Chapter 11 on November 2 in the U.S. Bankruptcy Court for the Southern District of Texas, with a prepackaged plan that gives the company to its lenders and merges it with Ayrmid Ltd., the parent of Gamida Cell. President and Chief Executive Officer Richard Paulson said the process offers "a clear framework to pursue a value maximizing transaction for our stakeholders." The plan cancels the common stock and the preferred stock with no distribution, and Karyopharm says it expects its existing equity to have no value. Against that, Karyopharm says it expects to pay trade creditors, employees and other general unsecured creditors in full, and the myelofibrosis application for XPOVIO cleared the FDA's 60-day filing review without a refuse-to-file letter. November 2 release · November 3 Form 8-K · Disclosure statement
What creditors get and what shareholders lose
Under the Ayrmid term sheet, holders of the term loan, both convertible note series and the DIP lenders receive 100% of the reorganized company's stock, which is exchanged at once for 55% of a new combined company. Ayrmid's existing stockholders take the remaining 45%. Debt holders also receive contingent value rights tied to future XPOVIO sales in myelofibrosis. Karyopharm says that approval is the principal driver of the value of its business and of those rights, so much of the creditors' upside rests on a decision the FDA has not made. November 3 Form 8-K
The disclosure statement estimates a 100% recovery for the roughly $129.0 million term loan and the $15.6 million of 2028 notes, but 78.9% for the $108.0 million of 2029 notes. Royalty investors owed $113.5 million under the revenue interest financing would swap that claim for a 3.0% royalty on selinexor net revenues for five years, an estimated 16.5% recovery. Those figures come from the sale process, with no separate valuation filed. The new company would be private, its shares unlisted, and Karyopharm expects Nasdaq to suspend and delist KPTI. Chief Financial Officer Lori Macomber signed the disclosure statement. Disclosure statement · November 3 Form 8-K
Highbridge sits on both sides
Ayrmid is majority-owned by funds managed by Highbridge Capital Management, LLC, and Highbridge funds also hold Karyopharm's term loans, 2028 notes and 2029 notes. The company says Highbridge recused itself from the sale process and the review of Ayrmid's proposal, and that the other members of the ad hoc group and their advisors negotiated the terms. Centerview Partners contacted 27 potential acquirors and 18 potential equity investors; 17 signed confidentiality agreements, and the company received five non-binding indications of interest. November 3 Form 8-K · Disclosure statement
Karyopharm itself calls the cash floor for a rival bid substantial. A competing bid must pay at least $335.4 million at closing, including at least $316.6 million in cash, and with unsecured claims and Ayrmid's protections the minimum successful payment is $363.6 million. Ayrmid would collect a break-up fee of 3% of the bid protection base plus expenses capped at 1% if it loses. November 3 Form 8-K
The DIP loan, the advisors and the clock
Existing lenders agreed to provide a debtor-in-possession facility of up to $110 million, subject to court approval, with Wilmington Savings Fund Society, FSB as agent. Only up to $55 million is new money, with an initial draw of up to $25 million once the court enters an interim order; the rest converts the funding lenders' prepetition term loans, $1.00 for each $1.00 of new money. New money bears SOFR, with a 3.00% floor, plus 9.00%, and roll-up loans SOFR plus 12.25%, both paid in kind, with exit fees of 4.00% and 8.00%. At closing a new term loan of up to $135 million would repay up to $50 million of the new money. Sidley Austin LLP, Centerview Partners LLC and FTI Consulting Inc. advise Karyopharm. Latham & Watkins LLP, Haynes and Boone LLP and Houlihan Lokey Capital, Inc. advise the ad hoc group, and Paul Hastings LLP advises Ayrmid. November 3 Form 8-K · November 2 release
Shareholders were still funding the company this year. In March, RA Capital Healthcare Fund, L.P. bought shares and warrants for net proceeds of $26.9 million, and at-the-market sales through Jefferies LLC raised $19.8 million in the first half. That day, the SENTRY trial met its spleen-volume co-primary endpoint, 49.8% against 28.0%, but missed its symptom-score co-primary endpoint. In September, the secured creditors took a $20.0 million forbearance fee in 20,000 preferred shares convertible at $1.62, which the plan now also cancels. Disclosure statement
At June 30, Karyopharm held $65.1 million in cash, cash equivalents and investments against an operating loss of $49.3 million for the first half, on total revenue of $68.5 million, including $59.9 million from XPOVIO. It reported substantial doubt about its ability to continue as a going concern and 22,681,460 shares outstanding as of August 6. It then missed a $15.8 million term loan installment on September 10. June quarter Form 10-Q · Disclosure statement
Creditors vote by November 30, 2026. Karyopharm asked for a combined confirmation hearing on or about January 11, 2027, expects the FDA's Day-74 letter on or about November 10, 2026, and expects the deal to close in the first quarter of 2027. November 3 Form 8-K
Investor Chat
Loading posts…
aibio